List of Excipients in Branded Drug ADZENYS XR-ODT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Neos Therapeutics Brands LLC	ADZENYS XR-ODT	amphetamine	70165-005	CELLULOSE, MICROCRYSTALLINE
Neos Therapeutics Brands LLC	ADZENYS XR-ODT	amphetamine	70165-005	CITRIC ACID MONOHYDRATE
Neos Therapeutics Brands LLC	ADZENYS XR-ODT	amphetamine	70165-005	CROSPOVIDONE
Neos Therapeutics Brands LLC	ADZENYS XR-ODT	amphetamine	70165-005	FRUCTOSE
Neos Therapeutics Brands LLC	ADZENYS XR-ODT	amphetamine	70165-005	MAGNESIUM STEARATE

ADZENYS XR-ODT Excipient Strategy, Formulation IP and Commercial Opportunities

Last updated: August 9, 2026

Adzenys XR-ODT is an extended-release, orally disintegrating tablet containing mixed amphetamine salts for attention-deficit/hyperactivity disorder. Its commercial differentiation comes from rapid oral disintegration, strawberry flavoring, dose flexibility, and elimination of the need to swallow a conventional tablet or capsule. The formulation creates opportunities in pediatric adherence, authorized-generic competition, taste masking, alternate stimulant delivery, and excipient supply. Its principal commercial constraints are Schedule II controls, stimulant competition, generic substitution, and the technical difficulty of reproducing extended release in an orally disintegrating dosage form.

What is Adzenys XR-ODT and how does its formulation work?

Adzenys XR-ODT was approved by the FDA in January 2016 under NDA 202514. Neos Therapeutics developed the product, and Tris Pharma later acquired Neos Therapeutics, including its commercial and development assets (FDA, 2016; Tris Pharma, 2022).

The product contains mixed amphetamine salts in a 3:1 ratio of d-amphetamine to l-amphetamine. It is approved for ADHD treatment in patients six years of age and older. The tablet is placed on the tongue, where it disintegrates without water. The drug is then swallowed and absorbed through the gastrointestinal tract.

Adzenys XR-ODT strengths and dose conversion

Adzenys XR-ODT strength	Approximate equivalent amphetamine mixed-salts dose
3.1 mg	5 mg
6.3 mg	10 mg
9.4 mg	15 mg
12.5 mg	20 mg
15.7 mg	25 mg
18.8 mg	30 mg

The product label states that Adzenys XR-ODT is not interchangeable on a milligram-for-milligram basis with other amphetamine products. Prescribers must use the conversion table and clinical judgment when switching products (FDA, 2024).

What excipients are used in Adzenys XR-ODT?

Adzenys XR-ODT uses a conventional orally disintegrating tablet excipient platform with functional components for compression, rapid breakup, flow, lubrication, taste, and product identity.

The FDA-approved label identifies the inactive ingredients as:

• Mannitol
• Silicified microcrystalline cellulose
• Crospovidone
• Colloidal silicon dioxide
• Magnesium stearate
• Sucralose
• Strawberry flavor

The exact commercial formulation and manufacturing process may include process controls and material specifications that are not fully disclosed in the public label.

Excipient function and commercial relevance

Excipient or excipient class	Primary function	Commercial significance
Mannitol	Diluent, water-soluble filler, mouthfeel modifier	Supports a cooling mouthfeel and rapid tablet breakup
Silicified microcrystalline cellulose	Compressibility and tablet structure	Helps maintain mechanical strength at low tablet weight
Crospovidone	Superdisintegrant	Drives rapid disintegration after contact with saliva
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces sticking and ejection force during compression
Sucralose	High-intensity sweetener	Masks amphetamine-associated bitterness
Strawberry flavor	Flavor and product acceptability	Supports pediatric administration and brand recognition

The combination is commercially important because orally disintegrating tablets face conflicting requirements. They must be strong enough to withstand packaging, shipping, and handling, but weak enough to disintegrate rapidly in the mouth. Excessive lubricant, high compression force, or poor particle-size control can slow disintegration and reduce dose uniformity.

How does the Adzenys XR-ODT excipient strategy create commercial value?

The excipient strategy targets adherence rather than pharmacologic novelty. Pediatric patients may resist capsules or tablets, while caregivers may have difficulty administering medication during school hours or travel. A flavored orally disintegrating tablet removes water as a required administration component and reduces the swallowing burden.

The main value drivers are:

1. Rapid disintegration without water.
2. Sweetened, flavored oral exposure.
3. Six marketed strengths for titration.
4. Extended-release delivery in a tablet that behaves like an immediate-use dosage form.
5. Reduced reliance on liquid measuring devices.
6. Potential utility for patients who have difficulty swallowing.

The strategy does not eliminate amphetamine taste. Flavor and sweetener reduce perceived bitterness, while rapid disintegration can limit the duration of unpleasant oral exposure. Taste masking remains a critical development issue because amphetamine salts are highly active at low doses and can be difficult to fully conceal.

What formulation patents protect Adzenys XR-ODT?

Adzenys XR-ODT is protected primarily through formulation, dosage-form, process, and regulatory exclusivity strategies rather than biologic protection. The relevant legal sources are the FDA Orange Book, issued patents, patent-family records, and any litigation or settlement filings.

The key patent categories are:

Protection category	Relevance to Adzenys XR-ODT
Orally disintegrating tablet composition	Covers the excipient matrix, drug loading, and disintegration profile
Extended-release delivery	Protects release-control technology and pharmacokinetic performance
Taste masking	May cover sweetener, flavor, coating, particle, or matrix combinations
Manufacturing process	May cover blending, compression, granulation, or coating conditions
Strength and dose design	Can support product-line protection across multiple dose levels
Method of treatment	May cover treatment of ADHD using the specific dosage form or dosing regimen

A public label does not disclose the full commercial formulation or all proprietary process parameters. Competitors can often use the same broad excipient classes while changing grades, ratios, particle sizes, manufacturing conditions, and release mechanisms. The enforceability of a formulation patent therefore depends on claim construction and whether a competing product falls within the claimed composition or process.

What is the FDA regulatory status of Adzenys XR-ODT?

Adzenys XR-ODT is an FDA-approved prescription drug under NDA 202514. It is a Schedule II controlled substance because it contains amphetamine, a central nervous system stimulant with abuse and dependence risks (FDA, 2024; U.S. Drug Enforcement Administration, 2024).

Regulatory characteristics

Item	Status
Active ingredient	Mixed amphetamine salts
Dosage form	Extended-release orally disintegrating tablet
Route	Oral
Approval pathway	NDA
Original approval	2016
Pediatric indication	ADHD, age six years and older
Controlled-substance schedule	Schedule II
Biosimilar pathway	Not applicable
Orange Book relevance	NDA patent and exclusivity listings govern listed protection

The product is not a biologic. Biosimilar risk is therefore irrelevant. Competitive entry would generally occur through an abbreviated new drug application, a 505(b)(2) application, an authorized generic, or a competing branded product, depending on the formulation and reference-product relationship.

When does Adzenys XR-ODT lose exclusivity?

Market exclusivity depends on several separate events:

• FDA regulatory exclusivity.
• Listed patent expiration.
• Pediatric exclusivity.
• Paragraph IV challenges.
• Litigation outcomes.
• Settlement dates.
• Generic approval and commercial launch decisions.

The FDA Orange Book is the controlling public source for current listed patents and regulatory exclusivity. A precise generic-entry date cannot be inferred from the original 2016 approval date alone. A listed patent can extend beyond regulatory exclusivity, while a patent challenge or settlement can alter the practical launch date.

How many patents cover Adzenys XR-ODT?

The answer depends on whether the analysis counts only patents listed in the Orange Book or the broader patent estate, including unlisted formulation, manufacturing, and continuation patents. Orange Book-listed patents are the most relevant to ANDA certification and Paragraph IV litigation. Unlisted patents may still affect 505(b)(2) products, manufacturing transactions, licensing negotiations, or trade-secret protection.

For commercial diligence, the relevant sequence is:

1. Review the current Orange Book entry for NDA 202514.
2. Identify each listed patent and expiration date.
3. Review continuation and divisional patent families.
4. Search Federal Court and Patent Trial and Appeal Board records.
5. Compare the proposed product’s excipients, release profile, and manufacturing process against the asserted claims.

What generic entry risks exist for Adzenys XR-ODT?

Generic entry risk is material but technically more complex than for a standard immediate-release amphetamine tablet. A challenger must reproduce the reference product’s critical pharmaceutical characteristics, including:

• Rapid oral disintegration.
• Extended-release exposure.
• Dose proportionality across strengths.
• Amphetamine enantiomer composition.
• Taste and mouthfeel.
• Stability in the commercial package.
• Content uniformity at low drug loading.
• Controlled-substance manufacturing and distribution controls.

A generic applicant may challenge listed patents through a Paragraph IV certification. The reference sponsor can file patent litigation within the statutory period, triggering a stay of approval for up to 30 months, subject to statutory exceptions and court action.

Which companies are challenging Adzenys XR-ODT?

Publicly confirmed challengers, Paragraph IV certifications, and settlement terms must be taken from current FDA, court, and company filings. The product’s competitive field includes manufacturers with experience in stimulant generics, orally disintegrating tablets, and controlled-release systems. A company may enter through an ANDA without immediately launching if litigation, supply constraints, or commercial economics make an early launch unattractive.

The absence of an immediate generic launch does not establish that the patent estate is strong. It may reflect manufacturing difficulty, limited market size, controlled-substance quotas, or settlement restrictions.

What manufacturing and IP barriers affect Adzenys XR-ODT?

Manufacturing is a meaningful barrier because the product must balance low tablet density, mechanical strength, rapid disintegration, and extended release.

Key technical barriers

Low-dose content uniformity

Amphetamine is potent, and some strengths contain a relatively small drug mass compared with the total tablet. Blend segregation, electrostatic charging, and inadequate mixing can create content-uniformity failures.

Compression and friability

Orally disintegrating tablets require a narrow compression window. Excessive force can produce a dense tablet with slow breakup. Insufficient force can cause chipping, friability, and packaging losses.

Taste exposure

The active ingredient must be masked without slowing drug release or increasing tablet size. Sweeteners and flavors alone may not provide sufficient masking for all patients.

Moisture sensitivity

Disintegration performance, flavor stability, and mechanical properties can change with humidity. High-barrier packaging and controlled manufacturing conditions may be necessary.

Controlled-substance compliance

Manufacturers must maintain DEA registration, quota access, inventory controls, diversion prevention, and auditable distribution systems. These requirements narrow the field of viable suppliers and contract manufacturers.

What commercial opportunities exist for excipient suppliers?

The strongest opportunities are in differentiated excipient systems rather than single commodity ingredients.

Modified mannitol and co-processed fillers

Suppliers can offer grades optimized for direct compression, low friability, rapid wetting, and improved mouthfeel. Co-processed mannitol-cellulose systems may reduce formulation development time.

Advanced taste-masking systems

Potential products include ion-exchange resins, lipid barriers, polymer coatings, and multiparticulate taste-masking platforms. The principal requirement is to reduce bitterness without delaying the intended extended-release profile.

Low-lubrication processing

Specialized lubricant systems or optimized magnesium stearate grades may preserve rapid disintegration while reducing tablet sticking and ejection force.

Flavor systems for pediatric products

Strawberry is the established product identity, but suppliers can develop flavor systems with improved stability, reduced aftertaste, and compatibility with sweeteners and controlled-release matrices.

Packaging and moisture control

High-barrier blister systems, desiccant-integrated packaging, and humidity-resistant unit-dose formats can protect tablet performance and support school, travel, and adherence use cases.

How does Adzenys XR-ODT compare with competing ADHD products?

Product type	Administration advantage	Principal limitation
Adzenys XR-ODT	Water-free, flavored ODT, extended release	Controlled substance and formulation complexity
Adderall XR	Established extended-release capsule	Requires swallowing or capsule-opening instructions
Vyvanse capsule or chewable	Multiple administration options	Higher cost and lisdexamfetamine-specific exposure
Quillivant XR	Liquid dosing flexibility	Measuring burden and storage requirements
Dyanavel XR	Liquid or chewable stimulant delivery	Taste, dosing, and formulation preferences vary
Immediate-release amphetamine tablets	Low cost and flexible titration	More frequent dosing and swallowing requirement

Adzenys XR-ODT occupies a narrow position: extended-release amphetamine delivery in a small, flavored, water-free dosage form. Its closest commercial competitors are other pediatric-friendly stimulant formulations, particularly liquids, chewables, and orally disintegrating products.

What is the revenue exposure and licensing opportunity?

Public company disclosures do not consistently report Adzenys XR-ODT revenue as a standalone line item. Revenue exposure should therefore be modeled from prescription volume, net price, payer coverage, conversion rates, and generic-entry timing rather than from a separately reported product figure.

Potential licensing opportunities include:

• Regional commercialization rights.
• Authorized-generic arrangements.
• Excipient or taste-masking licenses.
• Contract manufacturing partnerships.
• Pediatric stimulant portfolio acquisitions.
• Reformulation rights for new strengths or alternate flavors.
• Technology licensing for abuse-deterrent or tamper-resistant delivery.

The most valuable transaction asset is likely the combination of formulation know-how, regulatory history, controlled-substance infrastructure, and commercial access. An excipient alone is less defensible unless it is linked to performance data, a patent family, or a validated manufacturing process.

Key Takeaways

• Adzenys XR-ODT is an extended-release mixed-amphetamine-salts ODT approved for ADHD patients six years and older.
• Its excipient platform uses mannitol, silicified microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, sucralose, and strawberry flavor.
• The commercial proposition is water-free administration, pediatric acceptability, and dose flexibility.
• The main formulation challenge is balancing rapid disintegration, taste masking, mechanical strength, and extended release.
• Biosimilar risk does not apply because Adzenys XR-ODT is a small-molecule drug.
• Generic risk depends on current Orange Book patents, Paragraph IV certifications, litigation, settlements, and the technical feasibility of reproducing the dosage form.
• Excipient opportunities are strongest in co-processed fillers, taste masking, low-lubrication systems, pediatric flavors, and moisture-protective packaging.
• Revenue should be modeled from prescription and payer data because standalone Adzenys XR-ODT revenue is not consistently disclosed publicly.

FAQs

Is Adzenys XR-ODT an immediate-release or extended-release product?

It is an extended-release orally disintegrating tablet. Rapid tablet disintegration does not mean immediate-release pharmacokinetics.

Can Adzenys XR-ODT be substituted milligram-for-milligram with Adderall XR?

No. The FDA label provides specific conversion guidance and states that the products are not interchangeable on a milligram-for-milligram basis.

Which excipient is most important for Adzenys XR-ODT disintegration?

Crospovidone is the principal superdisintegrant, while mannitol and silicified microcrystalline cellulose influence wetting, structure, porosity, and mouthfeel.

Can a generic manufacturer use the same excipients as Adzenys XR-ODT?

It may use the same excipient classes if the formulation satisfies regulatory, patent, quality, and performance requirements. Exact excipient grades, ratios, process conditions, and release performance remain critical.

Is Adzenys XR-ODT eligible for biosimilar competition?

No. Adzenys XR-ODT is a small-molecule amphetamine product. Competition would generally involve an ANDA, 505(b)(2) product, authorized generic, or another branded stimulant formulation.

References

1. U.S. Food and Drug Administration. (2016). FDA approves first orally disintegrating amphetamine tablet for ADHD.
2. U.S. Food and Drug Administration. (2024). Adzenys XR-ODT prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Tris Pharma, Inc. (2022). Tris Pharma completes acquisition of Neos Therapeutics.
5. U.S. Drug Enforcement Administration. (2024). Drug scheduling and controlled substances.